Announcements
30 April 2025
Richard DiMarchi and Rolf Müller Share the 2024 Tu Youyou Award
We are pleased to announce that the 2024 Tu Youyou Award has been conferred upon Richard DiMarchi and Rolf Müller, in recognition of their significant contributions to natural products chemistry and medicinal chemistry.
 Richard DiMarchi Indiana University, USA |
Prof. Richard DiMarchi is a Distinguished Professor of Chemistry and Gill Chair in Biomolecular Sciences at Indiana University, USA. He is a member of the National Academy of Medicine and the National Inventors Hall of Fame. Dr. DiMarchi is a former Group Vice President at Eli Lilly and later at Novo Nordisk. He is recognized for his contributions to the discovery and development of rDNA-derived Humulin®, Humalog®, rGlucagon®, and Forteo®. His academic research has broadened the understanding of glucagon and incretin physiology and pioneered the discovery of single-molecule multi-mechanism agonists for the treatment of diabetes and obesity. The central element to success has been the chemical vision and technology to install within single molecules simultaneous agonism at related G-protein coupled receptors, coupled to the counter-intuitive discovery that glucagon and GIP agonism could synergize the therapeutic efficacy of GLP-1. These peptides and their conceptual approach have transformed the management of excessive body weight to a condition comparable to how hypertension, adult-onset diabetes, and excess cholesterol are medicinally managed. |
| “Professor DiMarchi was recognized by the 2024 Tu Youyou Award Committee members as being an exceptional leader in the medicinal chemistry of peptides and proteins of natural origin, and as a pioneer in the field of chemical biotechnology. His very important discoveries have led to breakthroughs in new drugs related to the therapy of diabetes and obesity. He has been named as an inventor on a very large number of patents, and he has had initially a highly successful scientific and administrative career in industry, which was followed by over two decades in academia as a distinguished professor.” —Prof. Dr. A. Douglas Kinghorn, Chair of the Award Committee |
|
 Rolf Müller Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Germany; Helmholtz Centre for Infections Research (HZI), Germany; Saarland University, Germany |
Prof. Rolf Müller is the Founding and Managing Director of the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) and Professor of Pharmaceutical Biotechnology at Saarland University, Germany. Having received his training from the University of Bonn, he held research positions at the University of Washington, USA, and Braunschweig University of Technology, Germany, prior to his appointment as professor to Saarland University. His laboratory has dedicated itself to the exploration of bacterial natural-product biosynthetic pathways for more than 20 years and has extensive experience in working with myxobacteria and other microbial producer strains. Starting from the isolation and characterization of new microorganisms, the scope of work includes microbiology-, biotechnology-, bioinformatics-, and chemistry-based approaches to exploit these isolates as sources of new drugs with a special focus on novel anti-infectives. Müller and his team apply a variety of state-of-the-art analytical methods and biological assays to perform biological and chemical characterizations of the identified compounds. Prof. Müller has received several awards, including the prestigious Gottfried Wilhelm Leibniz Prize, the PHOENIX Pharmacy Research Award, the DECHEMA Prize, and the Inhoffen Medal, as well as being an elected member of acatech, Leopoldina, and the German Academy of Sciences and Literature. |
| “The 2024 Tu Youyou Award Committee members were highly impressed by the truly outstanding past and ongoing contributions of Professor Müller in both microbial natural products isolation chemistry and in biosynthesis, as well as in the development of lead compounds for their potential in treating human diseases, through his global connections with various major funding agencies. He is also a dedicated teacher who has trained numerous graduate students and postdoctoral fellows, and he has lectured on his research in countries all over the world.” —Prof. Dr. A. Douglas Kinghorn, Chair of the Award Committee |
|
The achievements of Richard DiMarchi and Rolf Müller highlight the transformative impact of natural products chemistry and medicinal chemistry. We congratulate them and invite the global academic community and public to join us in celebrating their significant contributions.
2024 Award Committee
Committee Chair:
- Prof. Dr. A. Douglas Kinghorn, Ohio State University, USA.
Committee Members (listed in alphabetical order):
- Prof. Angelo Fontana, University of Naples “Federico II”, Italy;
- Prof. Binghe Wang, Georgia State University, USA;
- Dr. Diana Pinto, University of Aveiro, Portugal;
- Prof. Hideaki Kakeya, Kyoto University, Japan;
- Dr. RuAngelie Edrada-Ebel, University of Strathclyde, UK;
- Prof. Thomas Prisinzano, University of Kentucky, USA
- Prof. Wei Li, University of Tennessee Health Science Center, USA.
About the Tu Youyou Award:
The 2024 Tu Youyou Award includes a total monetary prize of 100,000 Swiss Francs and a medal for each recipient. Established in 2016 to honor the pioneering spirit of Nobel laureate Tu Youyou, the Tu Youyou Award is an international award honoring exceptional scholars dedicated to the fields of natural products chemistry and medicinal chemistry.
For further information about the award and the winners, please visit the Tu Youyou Award website.
30 April 2025
MDPI INSIGHTS: The CEO's Letter #22 - 300 Journals in WoS, Norway & Sweden Consortiums, Self-citations
Welcome to the MDPI Insights: The CEO's Letter.
In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.
Opening Thoughts
Over 300 MDPI Journals are Indexed in Web of Science
Indexing is essential to scholarly publishing as it promotes visibility and the impact of research. I’m excited to share that MDPI now has over 300 journals indexed in the Web of Science (WoS). This milestone reflects the work of our authors, editors, reviewers, and the entire MDPI staff, contributing to greater visibility and impact for open access research.
Publish with MDPI, publish with impact.
Having over 300 MDPI journals indexed in the Web of Science is more than a numbers game. It represents a recognition of the quality, consistency, and relevance of the research published in our journals. For the academic community, it reflects the growing trust in MDPI as a reputable publisher, leading the way in open access publishing.
A closer look at the achievement
Being indexed in the WoS nvolves meeting a list of quality criteria, including 24 quality benchmarks for ESCI journals.
For MDPI, rigorous editorial standards and scientific integrity are key. These enabled over 300 journals to pass the Web of Science quality criteria for indexing.
Here we share a blog post discussing the importance of this milestone for MDPI and open scholarly research. In this post, Constanze Schelhorn, Head of Indexing, at MDPI, and Giulia Stefenelli, Scientific Communications Lead, share their thoughts and insights on what this achievement means for our commitment to high-quality research.
“MDPI has a well-structured quality assurance framework that applies to all our journals. We also apply clear, standardized peer-review policies across our portfolio, ensuring transparency and consistency.” – Constanze Schelhorn, Head of Indexing
“This achievement is a step forward for Open Access research, reinforcing the mission to share scientific knowledge globally and facilitate research progress.” – Giulia Stefenelli, Scientific Communications Lead
Read the blog here: https://blog.mdpi.com/2025/04/03/300-mdpi-journals/
Looking to the future
This milestone is a testament to MDPI’s dedication to peer review, editorial excellence, and innovation in academic publishing. It highlights our role as leaders in open access publishing.
Personally, I see this as just the beginning. We will continue to support researchers, expand our contributions to scholarly communication, and push the boundaries of academic publishing.
Impactful Research
Nearly 920 partner institutions in MDPI’s Institutional Open Access Program
I’m pleased to share some exciting progress from MDPI's Institutional Open Access Program (IOAP), which now includes nearly 920 partner institutions worldwide. This is more than just a number. It reflects the growing trust and collaboration we’ve built with universities, libraries, and research organizations across the globe.
The IOAP offers institutions discounted Article Processing Charges (APCs), access to a dedicated institutional dashboard, and transparency throughout the publishing process.
Norway’s Sikt Consortium Renews national agreement with MDPI
MDPI has renewed its national agreement with the Sikt Consortium, which now supports 36 institutions across Norway. New partners, such as Kristiania University of Applied Sciences, join long-standing collaborators such as NTNU, the University of Bergen, and UiT, The Arctic University of Norway. The agreement promotes affordable, high-quality open access publishing through centralized APC funding, and reinforces Norway’s leadership in open science.
These agreements reflect MDPI’s mission to remove barriers to scientific publishing and make research freely available to all. By collaborating with national consortia and institutions, we advance the open access and strengthen our global network and collaborations.
Our IOAP Team
A big thank-you to our IOAP team for driving these important collaborations. Their work includes increasing MDPI’s visibility in scholarly communications, strengthening relationships with IOAP partners, and building trust with key stakeholders.
These efforts not only help researchers to publish their work openly and affordably but also reinforce MDPI’s position as a trusted leader in open access.
What are the benefits of MDPI’s IOAP?
For Authors: Researchers affiliated with IOAP partner institutions benefit from automatic discounts on APCs, Book Processing Charges (BPCs), JAMS, and Author Services across MDPI’s journals. The process is seamless as there is no need for codes or special applications. The publishing experience is smoother and more affordable, and centralized invoicing helps simplify the process, allowing authors to focus on their research rather than administration.
For Libraries: Participating libraries receive access to a dedicated institutional dashboard with live metadata on submissions from affiliated authors, past and present. They also benefit from flexible invoicing options (direct, collective, or prepayment) to help streamline administration, while clear, transparent agreements ensure that there are no hidden clauses or small print. Automated deposits into Institutional Repositories further reduce manual work, supporting libraries in their mission to advance open access and serve their research communities.
Inside MDPI
MDPI Self-citation study shows industry alignment
Earlier this month, Dr. Giulia Stefenelli and Dr. Enric Sayas published a thoughtful and transparent article on the ALPSP blog, presenting a self-citation analysis across MDPI’s 237 journals indexed in the Journal Citation Reports (JCR).
They found that MDPI's average self-citation rate in 2024 was 14.85%, well within industry norms and ranking 6th among the top ten publishers. Only 2.3% of MDPI journals were identified as outliers with high self-citation rates, compared to 4.7% among other leading publishers. An alternative approach, using weighted average by publication volume, shows MDPI’s self-citation rate rises from 14% to 19.7%, shifting our rank from 6th to 3rd. The study also shows that the impact of self-citation on journal quartile placement is minimal.
Read the full article on the ALPSP blog: https://blog.alpsp.org/2025/03/mdpi-self-citations-study-highlights.html
Why is this important?
As explained in the full article, the results “reinforce the fact that self-citations have minimal influence on MDPI journal rankings, emphasizing the integrity of editorial practices and the absence of any deliberate efforts to manipulate impact.”
Self-citation is a hot topic, and MDPI is sometimes unfairly singled out in this area. This analysis helps put some perspective to that narrative.
At MDPI, we are committed to transparency and to using data-driven insights to address common misconceptions about open access publishing. Our focus on self-citation reflects this commitment, and we plan to extend our efforts to other areas where the Gold OA model is often misunderstood.
About the authors
Dr. Giulia Stefenelli, Scientific Communications Lead, leverages her expertise in science communication, editorial processes, and Open Access (OA) promotion to address both institutional and country-specific challenges. She collaborates with teams across PR, Editorial Procedures, Institutional Partnerships, Research Integrity, AI and more, developing strategies to engage stakeholders, including policymakers, academics, and industry leaders. Her responsibilities include enhancing MDPI’s scientific network and promoting OA initiatives at events worldwide, supporting the efforts of various departments, and ensuring effective communication to both specialist and broader audiences.
Dr. Enric Sayas is a Business Analyst specializing in the integration of AI and Machine Learning in scientific publishing.
Within MDPI’s AI team, Enric combines his editorial expertise with his passion for AI to support the development of AI-driven solutions tailored to editorial needs, enhancing efficiency and improving decision-making.
Enric’s interests extend to data science methodologies applied to scientific publishing, as well as the broader impact of AI on open science, peer review, and the future of scientific publishing.
Coming Together for Science
Plants 2025: From Seeds to Food Security
Prof. Dr. Dilantha Fernando presenting at Plants 2025 in Barcelona, Spain.
The MDPI Conference Plants 2025: From Seeds to Food Security took place in Barcelona, Spain, from 31 March to 2 April 2025.
It was chaired by Editor-in-Chief of MDPI journal Plants (Q1 journal); Prof. Dr. Dilantha Fernando from the University of Manitoba, in Canada, and Section Editor-in-Chief of Plants; Dr. Fermín Morales from Instituto de Agrobiotecnología (IdAB) – CSIC, in Spain; and Prof. Dr. Oscar Vicente from Universitat Politècnica de València (UPV) in Spain.
The conference brought plant scientists together to discuss innovations in sustainable agriculture, crop improvement, and environmental conservation.
With the global population projected to reach 9.7 billion by 2050, the conference addressed key challenges such as food security, climate change, and sustainable agroecosystems through keynote talks and seven specialized sessions.
The conference gathered 111 attendees from 36 different countries, featuring 1 keynote speaker, 9 invited speakers, and 41 selected talks, along with 56 posters. The event received just over 200 submissions and 102 accepted abstracts.
From insightful talks, engaging poster sessions and engaging networking moments, Plants 2025 was a special experience. You can relive the highlights from the Plants 2025 conference here with our after movie!
Awards
Four awards were presented at the conclusion of the conference, sponsored by the journal Plants: two Best Poster Awards (€250 each) and two Best Oral Presentation Awards (€300 each).
Plants 2025 Conference Team
The Plants 2025 Conference was organized by colleagues from MDPI’s Conference Team: Ana Sanchis (Conference Manager), Cédric Spinnler (Senior Conference Organizer), Raquel Sellès (Conference Organizer) and Laura Perez (Conference Assistant).
Upcoming event
5–7 May 2025
The 2nd International Electronic Conference on Metals
Location: Online event (Central European Summer Time)
As one of the pillar technologies that support the development of modern society and metallurgy, IECME 2025 will present the state-of-the-art of Metallurgy and Metals.
Find more upcoming MDPI events here.
Closing Thoughts
Swedish consortium renews partnership with MDPI
I’m pleased to share that MDPI has renewed its national partnership with Sweden’s Bibsam Consortium. This is a continued commitment to advancing open access publishing and supporting Sweden’s vision for fully open research.
Under this renewed agreement, 22 leading institutions including KTH Royal Institute of Technology, Stockholm University, Linnaeus University, and Linköping University, will continue to benefit from MDPI’s IOAP. This provides discounts on APCs and a more streamlined, researcher-friendly publishing experience.
MDPI and Bibsam renew national agreement for Sweden
“With robust backing from national open science guidelines, Sweden’s open-access landscape is rapidly advancing,” says Becky Castellon, institutional partnerships manager at MDPI.
“In fact, fewer than 15% of all Swedish research outputs were locked behind paywalls in 2023. We are passionate about the positive impact our ongoing partnership with the Bibsam Consortium will have on Swedish research, paving the way for ground-breaking developments and a more inclusive, open scientific community. Through flexible solutions and tailored policies, we enable institutions to prioritize research, foster innovation, and enhance accessibility, driving the shift to full open access.”
Recent MDPI IOAP Consortium signings from 2025:
- The UK’s Jisc Consortium extended its national agreement, continuing support for more than 60 institutions across the UK.
- Switzerland’s CSAL (Consortium of Swiss Academic Libraries) renewed its agreement, continuing our collaboration with top institutions such as ETH Zurich and EPFL Lausanne.
- In Germany, we signed a new national agreement with ZB MED that includes over 100 universities and research institutions, with 78 institutions joining under a central or flat-fee model to simplify APC coverage.
Chief Executive Officer
MDPI AG
30 April 2025
Announcing the Award Committee for the 2024 Tu Youyou Award
We are honored to introduce the award committee for the 2024 Tu Youyou Award, composed of distinguished scientists from around the world whose research covers diverse areas of natural product chemistry, pharmacognosy, and drug discovery. Their broad expertise and pioneering contributions have significantly advanced medicinal and natural products research.
Through their collective insights, rigorous evaluation, the committee has carefully selected this year’s award recipients, recognizing exceptional achievements in the field.
We sincerely thank these distinguished scholars for their efforts and dedication to upholding the standards of the Tu Youyou Award. Below is the list of committee members. For more information about the Tu Youyou Award, please visit https://tuyouyouprize.org/.
Chair:
 Prof. Dr. A. Douglas Kinghorn Ohio State University, USA |
Prof. Dr. A. Douglas Kinghorn is a leading expert in pharmacognosy and natural products research. He is recognized for his key contributions to discovering bioactive compounds from plants, especially in anticancer, cancer chemopreventive, and substances with a sweet taste and taste-modifying agents. His prolific contributions include over 590 peer-reviewed works and book chapters and edited or co-edited 40 scientific volumes. |
 Prof. Angelo Fontana University of Naples “Federico II”, Italy |
Angelo Fontana is a Professor of Organic Chemistry at the University of Naples “Federico II” in Italy and serves as Director of the Institute of Biomolecular Chemistry at the National Research Council (CNR). His research focuses on bioactive small molecules derived from marine eukaryotes, with a particular interest on their pharmaceutical applications in immunology and oncology. He also explores their potential as molecular tools for probing and modulating complex biological systems. Prof. Fontana is a co-founder of BioSEArch SRL and has been recognized with numerous grants and honors, including the Apivita Award from the Phytochemical Society of Europe. |
 Prof. Binghe Wang Georgia State University, USA |
Prof. Binghe Wang’s lab works on drug design, drug delivery, click chemistry, chemical biology, new diagnostics, and gaseous signaling molecules such as carbon monoxide and hydrogen sulfide. His interdisciplinary research supports advances in cancer, infectious diseases, organ protection, inflammation, and other areas. |
 Dr. Diana Pinto University of Aveiro, Portugal |
Dr. Diana Pinto, an Associate Professor at the University of Aveiro, specializes in organic synthesis of bioactive heterocyclic compounds, sustainable catalysis (organo-, heterogeneous, and biocatalysis), and natural product research, including isolation, characterization, and total synthesis. |
 Prof. Hideaki Kakeya Kyoto University, Japan |
Prof. Hideaki Kakeya conducts cutting-edge research in chemical biology, high-throughput screening, and biosynthesis of bioactive natural products for system chemotherapy and other therapeutic applications. |
 Dr. RuAngelie Edrada-Ebel University of Strathclyde, UK |
Prof. RuAngelie Edrada-Ebel heads the Natural Products Metabolomics Group (NPMG), specializing in marine natural products discovery and metabolomics-driven drug development. A recognized expert in bioactive metabolites, she collaborates with industry and academia to address antimicrobial resistance and sustainable bioprospecting. She serves on the Editorial Board of Marine Drugs and holds two patents in the field. |
 Prof. Thomas Prisinzano University of Kentucky, USA |
Prof. Thomas Prisinzano combines medicinal and natural product chemistry to explore neurotransmitter systems and develop treatments for drug abuse and pain. He has received several prestigious awards, including the Innovator Award from the College on Problems of Drug Dependence. |
 Prof. Wei Li University of Tennessee Health Science Center, USA |
A distinguished professor and Director of the Drug Discovery Center, Prof. Wei Li is also the founder of SEAK Therapeutics, and the 2025 Chair-Elect of the Drug Discovery and Development Division of the American Society of Pharmacology and Experimental Therapeutics (ASPET). His work focuses on medicinal chemistry and small molecule drug discovery, with over 200 publications and 15 issued US patents. |
17 April 2025
World Hemophilia Day—“Access for All: Women and Girls Bleed Too”, 17 April 2025
On 17 April 2025, the global bleeding disorders community will come together to celebrate World Hemophilia Day. This year’s theme is “Access for all: Women and girls bleed too”.
Currently, women and girls with bleeding disorders (WGBDs) are still underdiagnosed and underserved. The global bleeding disorders community has the power—and the responsibility—to change this. Through recognition, diagnosis, treatment, and care, the quality of life of women and girls will improve, strengthening the community as a whole.
We would like to recommend some related articles, Special Issues, and MDPI journals as suitable communication platforms and believe that sharing research like this can help raise awareness of Hemophilia Day.
 |
 |
 |
 |
 |
 |
 |
 |
 |
“Managing Surgical Risks in Hemophilic Elbow Arthropathy: An In-Depth Case Study and Literature Review”
by Gianluigi Pasta, Salvatore Annunziata, Roberta Ruggieri, Dario Abruzzi, Paolo Arrigoni, Eugenio Jannelli, Francesco Benazzo, Luisella Pedrotti, Erika Maria Viola, Emérito Carlos Rodriguez-Merchan and Mario Mosconi
Healthcare 2024, 12(17), 1776; https://doi.org/10.3390/healthcare12171776
“Better Communication for Better Management of Persons with Hemophilia: Results from a Patients’-Clinicians’ Project to Address the New Therapeutic Landscape”
by Laura Banov, Silvia Linari, Luigi Ambroso, Enrico Ferri Grazzi, Samanta Gallo, Patrizio Pasqualetti and Maria Elisa Mancuso
J. Clin. Med. 2024, 13(2), 568; https://doi.org/10.3390/jcm13020568
“Six-Year, Real-World Use of Prophylaxis with Recombinant Factor IX–Albumin Fusion Protein (rIX-FP) in Persons with Hemophilia B: A Single-Center Retrospective–Prospective Study”
by Antonio Coppola, Gianna Franca Rivolta, Gabriele Quintavalle, Annalisa Matichecchia, Federica Riccardi, Rossana Rossi, Anna Benegiamo, Paola Ranalli, Valeria Coluccio and Annarita Tagliaferri
J. Clin. Med. 2024, 13(5), 1518; https://doi.org/10.3390/jcm13051518
“Thalassemia: Pathophysiology, Diagnosis, and Advances in Treatment”
by Idris Zubairu Sadiq, Fatima Sadiq Abubakar, Hauwa Salisu Usman, Aliyu Dantani Abdullahi, Bashiru Ibrahim, Babangida Sanusi Kastayal, Maryam Ibrahim and Hassan Aliyu Hassan
Thalass. Rep. 2024, 14(4), 81-102; https://doi.org/10.3390/thalassrep14040010
“Haemophilia A: A Review of Clinical Manifestations, Treatment, Mutations, and the Development of Inhibitors”
by Sarmiento Doncel, Samuel, Gina Alejandra Díaz Mosquera, Javier Mauricio Cortes, Carol Agudelo Rico, Francisco Javier Meza Cadavid and Ronald Guillermo Peláez
Hematol. Rep. 2023, 15(1), 130-150; https://doi.org/10.3390/hematolrep15010014
“Ultrasound Evaluation of Tendinopathy in Hemophiliac Patients for the Purpose of Rehabilitation Indications”
by Danilo Donati, Paolo Spinnato, Lelia Valdrè, Lydia Piscitelli, Giuseppina Mariagrazia Farella, Enrico Pagliarulo and Maria Grazia Benedetti
J. Clin. Med. 2023, 12(13), 4513; https://doi.org/10.3390/jcm12134513
“Safe and Successful Surgical Outcome in Persons with Hemophilia A with and without Inhibitors Treated with Emicizumab: A Large, Single Center, Real-World Experience”
by Giancarlo Castaman, Silvia Linari, Lisa Pieri, Christian Carulli, Paolo Prosperi, Paolo Tonelli, Francesco Demartis, Rajmonda Fjerza, Monica Attanasio, Mirella Coppo and Francesca Salvianti
J. Clin. Med. 2023, 12(6), 2317; https://doi.org/10.3390/jcm12062317
“A Retrospective Analysis of the American Thrombosis and Hemostasis Network Dataset Describing Outcomes of Dental Extractions in Persons with Hemophilia”
by Heather Messenger, Roshni Kulkarni, Michael Recht and Chunla He
J. Clin. Med. 2023, 12(5), 1839; https://doi.org/10.3390/jcm12051839
“Laboratory Rat Thrombi Lose One-Third of Their Stiffness When Exposed to Large Oscillating Shear Stress Amplitudes: Contrasting Behavior to Human Clots”
by Ursula Windberger, Veronika Glanz and Leon Ploszczanski
Int. J. Transl. Med. 2022, 2(3), 332-344; https://doi.org/10.3390/ijtm2030026
2 April 2025
MDPI INSIGHTS: The CEO's Letter #21 - Annual Report, Swiss Consortium, IWD, ICARS, Serbia
Welcome to the MDPI Insights: The CEO's Letter.
In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.
Opening Thoughts
MDPI Releases 2024 Annual Achievements Report
I’m pleased to share the release of MDPI’s 2024 Annual Achievements Report, which reflects our commitment to efficiency, transparency, and excellence in scholarly communication. The report showcases key themes related to our growth (highlighting our workforce expansion, new offices, journal milestones), excellence (editorial and publishing advancements), people (talent development and training), and community (partnerships, conferences, and outreach).
MDPI continues to build connections and drive scientific progress
Our mission remains clear: to support researchers worldwide by delivering an efficient, high-quality publishing experience while strengthening the global Open Access (OA) movement.
Advancing Open Access: A Global Knowledge Hub
In 2024, we published 238,000 peer-reviewed OA articles, reaching over 25 million downloads. This reinforces MDPI’s role as a global knowledge hub, breaking down barriers to access and ensuring that high-quality research is freely available to everyone. As part of the OA movement, we are actively democratizing knowledge, making scientific advancements accessible to researchers, policymakers, educators, and the public, without the restrictions of traditional paywalls.
Expanding our Workforce and Strengthening Research Integrity
Our global presence grew in 2024 with the opening of a new Seoul office, and our workforce expanded to 6,650 staff across 21 offices. This reflects our continued growth mindset and investment in global accessibility. We also continued to take a proactive stance on our commitment to research integrity, tripling our team in this area and joining STM’s Integrity Hub and United2Act. This means more rigorous quality control, stronger safeguards, and collaboration with global initiatives to detect and combat unethical publishing practices at an industry level. Our growth is about reinforcing our role as a trusted, ethical, and accessible publishing platform for researchers worldwide.
Growing Partnerships and Impact in Scholarly Communication
MDPI’s partnerships continue to thrive, with over 900 institutional collaborations, including a landmark agreement with ZB MED in Germany, covering more than 100 universities. Additionally, more than 90% of evaluated MDPI journals have been accepted into Web of Science, including 60 new acceptances in 2024, with nearly 300 journals expected to receive a Journal Impact Factor in 2025. In the same period, 37 MDPI journals were accepted into Scopus, bringing our total indexed titles to 306. Most importantly, 95% of authors rate their experience with MDPI as excellent or good – an achievement that underscores our dedication to serving the research community.
I encourage you to read through our Annual Report, which highlights these milestones and our vision for the future. Thank you for being part of MDPI’s journey in advancing open science.
Impactful Research
MDPI Renews Partnership with CSAL to Support Swiss Universities
I am pleased to announce the renewal of our partnership with the Consortium of Swiss Academic Libraries (CSAL) for 2025. This extension reinforces MDPI's dedication to advancing open science through transparency, efficiency, and collaboration.
Our renewed agreement with CSAL strengthens support for Swiss universities, ensuring that gold open access publishing remains both accessible and affordable for researchers across Switzerland. Among the institutions participating in this agreement are ETH Zurich and EPFL Lausanne, along with 20 other leading institutions, further expanding the reach and impact of our collaborative efforts.
To date, over 3.9 million researchers have published their findings in MDPI journals, a testament to our role in enhancing Switzerland's position as a hub for university education and research.
Inside MDPI
Celebrating International Women's Day: Accelerating Action
In honour of International Women's Day, MDPI embraced the theme “Accelerate Action,” a global call to advance women's progress by implementing effective strategies and resources. As part of our commitment, we highlighted how open access publishing empowers female voices in research and academia.
Throughout March, we featured original blogs authored by MDPI’s female contributors, showcasing the successes of our journals and employees, and addressing pressing topics such as women's health.
“Open Access supports women in education”
Women Accelerating Action Outside of MDPI
MDPI employee Ana Zdravkovic is accelerating action outside of her MDPI role as a Production Assistant. Working with like-minded women at the award-winning Belgrade-based organization UZOR OsnaŽene (meaning ‘empowered women’), they identify serious flaws in cybersecurity, and help protect women and children against online predators by providing evidence to improve legislation and laws around cyber-attacks.
In this article, we interview Ana, celebrating the important and inspiring work that she and the organisation do.
How Open Access Supports Women in Education
Every day, women and girls face barriers in education or career progression. This is caused by a range of factors, including social expectations, poverty, and poor infrastructure.
Quality opportunities and participation in the education system by women is essential to achieving equality and fulfilling their human rights.
Here, we examine how Open Access supports women in education by removing barriers and ensuring that vital research is accessible.
Recent Advancements in Research on Endometriosis
March is Endometriosis Action Month. Endometriosis is a medical condition affecting women and young girls of reproductive age, often causing symptoms such as severe pelvic pain, irregular periods, and infertility.
More research on endometriosis is still urgently needed.
This research will help develop efficient diagnoses and better treatment for those struggling with the condition.
In this article, we explore what endometriosis is and discuss the latest research advancements on the disease.
We also curated a selection of MDPI journals, articles, and Special Issues focusing on gender equity, women in the workplace, and women’s health. Find out more about these by visiting our IWD – Accelerate Action landing page.
As I reflect on the month of March and International Women’s Day, I would like to take a moment to recognize and thank all of the incredible women at MDPI for your dedication to democratizing knowledge and shaping open access. Your contributions are invaluable, and they continue to shape the future of MDPI.
Coming Together for Science
The International Conference on Advanced Remote Sensing (ICARS 2025)
The International Conference on Advanced Remote Sensing (ICARS 2025) took place from 26–28 March 2025, in Barcelona, Spain. It was chaired by Prof. Dr. Fabio Tosti from the Faringdon Research Centre for Non-Destructive Testing and Remote Sensing (UK), Prof. Dr. Andrea Benedetto from University Roma Tre (Italy), and Prof. Dr. Luis Ángel Ruiz from Universitat Politècnica de València (UPV, Spain).
Over three days, the conference explored innovations in Earth and environmental sciences, engineering advancements, and practical applications in biological and agricultural fields.
I am pleased to share that the 1st edition of ICARS 2025 was a great success, with 133 attendees out of 146 registrations. The event featured 43 short talks, 64 posters, and 103 accepted abstracts, along with nine keynote speakers and a major panel with five expert panellists.
Over 60 attendees joined the conference dinner, and the event received outstanding feedback.
The main goal of ICARS2025 was to cover how advanced remote sensing technologies are transforming our approach to global challenges.
Awards
Four awards were presented at the conclusion of the conference, sponsored by the journal Remote Sensing: Best Poster Award (€400), Best Oral Presentation Award (€400), and two Early Career Researcher Awards (1st prize: €600 and 2nd prize: €200).
Thank you to our Partnering Societies
We are grateful for the support of our four partnering societies and nine media partners, who played an important role in promoting the conference. Special thanks to our partnering societies: the European Federation of Geologists (EFG), Geoscience Energy Society of Great Britain (GESGB), Asociación Española de Teledetección (AET) – the Spanish Association of Remote Sensing, and the International Society for Digital Earth (ISDE).
Upcoming In-Person Event
31 March–2 April 2025
Plants 2025: From Seeds to Food Security
Location: Barcelona, Spain
This event will gather plant scientists to discuss the latest research on how to feed a growing population while maintaining a sustainable agro-ecosystem.
Find more upcoming MDPI events here.
Closing Thoughts
MDPI Serbia Salon 2025: A Gathering of Academic Excellence
On Tuesday, 18 March, we successfully concluded our first MDPI Serbia Salon in Belgrade. This event provided a great opportunity to showcase MDPI’s achievements, strengthen connections with the Serbian academic community, and highlight our role as the largest publisher in Serbia. We were honoured to welcome Prof. Dr. Sergej M. Ostojić, Editor-in-Chief of MDPI journal Clinical Bioenergetics, as a guest speaker.
Over the past five years, MDPI has experienced continuous growth in Serbia, with an increasing number of publications, an expansion of Editorial Board memberships, and a greater number of active peer reviewers. The Salon allowed us to express our thanks to the Serbian research community while gathering feedback from attendees representing several major universities.
Discussion topics
As part of the event, I delivered an opening speech highlighting MDPI’s achievements and direction.
The event featured presentations from MDPI colleagues, including discussions on open science, publishing ethics, and our achievements in Serbia.
A special thank-you to all our MDPI presenters, panellists, and organizers who made his event a success. I hope the MDPI Serbia Salon becomes a tradition for years to come, creating connections within the Serbian research community.
Visit to the Science Fund of Serbia and The Ministry of Science
During my visit to Belgrade, I had the opportunity to join my colleagues Emir Ramadani (Operations Manager) and Nevena Blagojev (Journal Relations Manager) in meetings with the Science Fund of Serbia and the Ministry of Science, where we received strong support for our work in Serbia.
Both organizations highly value our presence in and commitment to Serbia, where we employ over 640 staff across our two offices in Belgrade and Novi Sad. We take great pride in creating job opportunities and supporting the community in Serbia.
“There’s a lot of exciting activity happening in MDPI Serbia”
Speaking with our Serbian Colleagues
Finally, I had the opportunity to speak with our Serbian colleagues about our initiatives to expand and to improve our marketing & communication and public relations activities.
It was great to have an open discussion with colleagues – both in person and with the hundreds who joined online.
This visit to Belgrade had been a long time coming for me. Serbia is our largest operation in Europe and there’s a lot of exciting activity happening in MDPI Serbia, including the launch of a new office floor in Novi Sad and the growth and expansion of our teams.
I look forward to returning soon and continuing to support our colleagues across our Serbian offices.
Chief Executive Officer
MDPI AG
27 February 2025
Rare Disease Day, 28 February 2025
28 February 2025 is the 18th International Rare Disease Day. The establishment of this international day aims to further increase the public’s attention and awareness of rare diseases, promote the popularization of rare diseases, promote the screening, diagnosis and prevention of rare genetic diseases, and improve the quality of life.
Rare diseases usually refer to diseases with a very low incidence rate. The World Health Organization defines diseases with a prevalence rate between 0.065% and 0.1% of the total population as rare diseases. Rare diseases do not refer to a specific disease but constitute a general term for diseases with a low incidence rate that occur in various systems. Although the incidence rate of a single rare disease is low, there are many types, currently more than 7,000, and the total number of patients with rare disease is quite high. According to statistics, there are more than 300 million patients with rare diseases in the world. Rare diseases are mostly chronic and serious diseases that often endanger life.
In recognition of this day, we recommend the following related articles, Special Issues, and journals spanning multidisciplinary fields, including clinical medicine areas and society areas. We believe that sharing such research can raise the public’s awareness and understanding of rare diseases. By disseminating these findings, we hope to inspire positive change, promote scientific education on rare diseases, and promote the screening, diagnosis and prevention of rare genetic diseases.
 |
||
 |
 |
 |
 |
 |
 |
 |
||
“Evaluation of ACR TI-RADS for Predicting Malignancy in Thyroid Nodules: Insights from Fine-Needle Aspiration Cytology and Histopathology Results”
by Ahmed Alsibani, Mohammed Alessa, Fahad Alwadi, Shams Alotaibi, Hana Alfaleh, Ali M. Moshibah, Abdullah M. Alqahtani, Abdulwahed AlQahtani, Mohammad Almayouf, Saleh F. Aldhahri et al.
J. Oman Med. Assoc. 2024, 1(1), 61-68; https://doi.org/10.3390/joma1010007
“Endoscopic Guided Dilations without Intralesional Corticosteroid Injections: Pediatric Crohn’s Patients Case Series”
by Leo Fawaz, Yousif Slim and Peter N. Freswick
Reports 2024, 7(4), 81; https://doi.org/10.3390/reports7040081
“Self-Reported Medication Adherence Measured with Morisky Scales in Rare Disease Patients: A Systematic Review and Meta-Analysis”
by Ana María García-Muñoz, Desirée Victoria-Montesinos, Begoña Cerdá, Pura Ballester, Eloisa María de Velasco and Pilar Zafrilla
Healthcare 2023, 11(11), 1609; https://doi.org/10.3390/healthcare11111609
“Epidermolysis Bullosa—A Kindler Syndrome Case Report and Short Literature Review”
by Bogdan Ioan Stefanescu, Diana Sabina Radaschin, Geta Mitrea, Lucretia Anghel, Adrian Beznea, Georgiana Bianca Constantin and Alin Laurentiu Tatu
Clin. Pract. 2023, 13(4), 873-880; https://doi.org/10.3390/clinpract13040079
“Blastic Plasmocytoid Dendritic Cell Neoplasm (BPDCN): Clinical Features and Histopathology with a Therapeutic Overview”
by Gerardo Cazzato, Marialessandra Capuzzolo, Emilio Bellitti, Giovanni De Biasi, Anna Colagrande, Katia Mangialardi, Francesco Gaudio and Giuseppe Ingravallo
Hematol. Rep. 2023, 15(4), 696-706; https://doi.org/10.3390/hematolrep15040070
“Changes in Hematologic Lab Measures Observed in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with C5 Inhibitors, Ravulizumab and Eculizumab: Real-World Evidence from a US Based EMR Network”
by Jesse Fishman, Seth Kuranz, Michael M. Yeh, Kaylen Brzozowski and Herman Che
Hematol. Rep. 2023, 15(2), 266-282; https://doi.org/10.3390/hematolrep15020027
“New-Generation Ektacytometry Study of Red Blood Cells in Different Hemoglobinopathies and Thalassemia”
by Elena Krishnevskaya, Marta Molero, Águeda Ancochea, Ines Hernández and Joan-Lluis Vives-Corrons
Thalass. Rep. 2023, 13(1), 70-76; https://doi.org/10.3390/thalassrep13010007
“Widespread and Long-Enduring Hyperkeratosis Lenticularis Perstans (Flegel’s Disease): Clinico-Pathological and Dermoscopic Features of a Rare Presentation”
by Giorgio Stabile, Giovanni Paolino, Nathalie Rizzo and Franco Rongioletti
Dermatopathology 2023, 10(1), 46-51; https://doi.org/10.3390/dermatopathology10010006
“Rare Variants of Dermatofibrosarcoma Protuberans: Clinical, Histologic, and Molecular Features and Diagnostic Pitfalls”
by Celestine M. Trinidad, Sintawat Wangsiricharoen, Victor G. Prieto and Phyu P. Aung
Dermatopathology 2023, 10(1), 54-62; https://doi.org/10.3390/dermatopathology10010008
“Repositioning Drugs for Rare Diseases Based on Biological Features and Computational Approaches”
by Belén Otero-Carrasco, Lucía Prieto Santamaría, Esther Ugarte Carro, Juan Pedro Caraça-Valente Hernández and Alejandro Rodríguez-González
Healthcare 2022, 10(9), 1784; https://doi.org/10.3390/healthcare10091784
 |
|
 |
Innovative Therapies and Management of Complications in Hemoglobinopathies” Guest Editors: Dr. Sophia Delicou and Prof. Dr. Constantina Politis Submission deadline: 31 May 2025 |
27 February 2025
More than 300 MDPI Journals Indexed in Web of Science
MDPI is pleased to share a significant milestone in its mission to advance scholarly research and promote the dissemination of knowledge—300+ MDPI journals are now indexed in Web of Science (WoS). This milestone highlights the global recognition, interdisciplinary impact and enhanced visibility of our journals. It also reflects our adherence to rigorous editorial standards, scientific integrity, and our mission to foster open scientific exchange in all forms, across all disciplines.
To explore the full list of our journals indexed in WoS, please visit https://www.mdpi.com/about/journals/wos. Beyond expanding the coverage of our publications in the leading academic databases, we are dedicated to ensuring that our journals are included in as many scope-specific databases as possible. This increases the visibility of our authors’ work and extends the reach of their significant data.
This milestone would not have been possible without the efforts and expertise of our academic editors, reviewers and authors. Their commitment and collaboration have been instrumental in creating an inclusive, accessible, and impactful publishing platform. We also extend our gratitude to the global research community for their trust as we continue to break new ground in academic publishing. This milestone is not just a celebration of MDPI’s progress but also recognition of the collective strides made by researchers worldwide.
As we celebrate this remarkable accomplishment, MDPI remains steadfast in its commitment to open access publishing and ensuring that high-quality research reaches and inspires a global audience.
17 February 2025
MDPI Celebrates Excellence in Medical Research with Early Career Researcher Awards
MDPI, a pioneer in scholarly open access publishing, and the Lee Kong Chian School of Medicine (LKCMedicine), Singapore, proudly announce the successful conclusion of the first edition the MDPI Early Career Researcher Awards. The awards, which recognize outstanding contributions to medical and biomedical research, were presented to six exceptional researchers during an awards ceremony held at LKCMedicine HQ Building on 28 November 2024.
|
|
|
Honoring Excellence in Research
The awards recognize exceptional postdoctoral researchers and Ph.D. students who have demonstrated outstanding originality, innovation, and impact in their respective fields. We are honored to announce the winners of the 2024 edition:
Early Career Researcher (Postdoc) Award:
- Dr. Theresia Handayani Mina, “Adiposity and Metabolic Health in Asian Populations: An Epidemiological Study Using Dual-Energy X-Ray Absorptiometry in Singapore”;
- Dr. Erfan Rezvani Ghomi, “Wound Healing Improvement by Novel Aligned Antimicrobial Nanofibrous 3D Scaffolds”;
- Dr. Yadollah Ranjbar Slamloo, “Functional Alterations of The Prefrontal Circuit Underlying Cognitive Aging in Mice”.
Early Career Researcher (Ph.D.) Award:
- Pritisha Rozario, “Mechanistic Basis for Potassium Efflux-Driven Activation of the Human NLRP1 Inflammasome”;
- Michelle Law Cheok Yien, “Chikungunya Virus Nonstructural Protein 1 is a Versatile RNA Capping and Decapping Enzyme”;
- Yin Ruoyu, “The Use of Digital Mental Health and Wellbeing Tools in Older Adults: A Mixed Method Study”.
Our collaboration highlights a shared commitment to recognizing exceptional talent and research within the academic community, addressing today’s healthcare challenges, and inspiring continued innovation.
|
|
|
|
|
|
|
|
|
Looking Ahead to 2025
Building on the success of the first edition, MDPI and LKCMedicine are excited to announce that the 2025 MDPI Early Researcher Awards will continue to celebrate excellence and innovation in medical research. The next edition promises to expand its scope, introducing new categories and providing even greater recognition for impactful research.
Further details on the 2025 awards, including nomination criteria and timelines, will be shared in the coming months. We remain committed to fostering a culture of research excellence and collaboration within the global scientific community.
|
|
5 February 2025
MDPI INSIGHTS: The CEO's Letter #20 - Beijing, Singapore, Bangkok, JAMS, Jisc
Welcome to the MDPI Insights: The CEO's Letter.
In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.
Opening Thoughts
2024 Annual Meeting – Beijing (15 January 2025)
You haven’t truly experienced a New Year’s celebration until you’ve attended one of MDPI’s Chinese Annual Meeting festivities. This year I visited our annual meeting in Beijing, held on the 15th of January.
Imagine this: stepping into a banquet hall filled with 140 tables and about 1,400 colleagues from our Beijing offices, all gathered to share in a six-hour event. The agenda included year-end speeches and presentations, a variety of performances by our colleagues, a selection of awards honouring local employees for their work, group photos for the memories, and a dinner.
This may have been one of the largest events I have attended. For those unaccustomed to such an event, it might seem overwhelming, but it was quite the opposite. The atmosphere was one of celebration as everyone came together to support their peers and celebrate the achievements of 2024.
I was honoured to deliver the opening speech and a presentation highlighting our growth and investment in MDPI’s most valuable asset: our people.
“Our editorial teams represent MDPI at its finest”
I want to give special recognition to the editorial department, across all of our offices, which forms the heart of our business. These teams are the frontline communicators with our authors, reviewers, and guest editors, creating a smooth experience of processing our manuscripts. Their professionalism and kindness are often highlighted as key drivers of satisfaction with MDPI. For this, I extend my deepest gratitude to all our editorial staff, across every office. They truly represent MDPI at its finest.
Beijing is home to two of our offices, with just over 800 employees in Tongzhou and over 600 in Haidian. Thank you to our administrative teams and everyone involved in organizing these New Year’s celebrations across all offices. These events provide a moment to reflect on our shared accomplishments and appreciate the positive impact each of you has on our culture.
MDPI Offices in China
While the history of MDPI begins in Basel, Switzerland, the story of MDPI is very much rooted in China. Below is a list of MDPI’s current offices in China and their respective dates of inauguration:
- 2008: Beijing (Tongzhou, Haidian)
- 2013: Wuhan (Hankou, Guanggu)
- 2019: Tianjin
- 2021: Dalian
- 2021: Nanjing
To date, over 381,000 MDPI research articles have been published by authors affiliated with Chinese institutions, making China our largest market. This is reflected not only in the volume of publications but also in the scale of our workforce supporting local operations and contributing to global success.
While no new offices in China were launched between 2022 and 2024 due to the pandemic and strategic planning, we remain committed to future growth here. Our plans include expanding operations as we continue to build our global workforce.
We look forward to a year filled with continued collaboration, growth, and shared success.
“We remain committed to future growth in China”
Impactful Research
MDPI and Jisc Consortium Extend Open Access Agreement for 2025
I’m pleased to share that MDPI has extended its agreement with the Jisc consortium in the UK for 2025. This renewal strengthens our partnership with UK institutions and reaffirms our shared commitment to advancing open access publishing.
Jisc is the UK’s not-for-profit digital, data, and technology agency supporting tertiary education, research, and innovation. Through initiatives such as our agreement, Jisc helps institutions access essential digital resources and infrastructure to support researchers. Currently, 62 UK institutions are part of our Institutional Open Access Program (IOAP) through this partnership.
Authors from participating institutions benefit from discounts on article processing charges (APCs), with even greater support for institutions that centrally fund APCs. This helps researchers focus on their work while simplifying the publishing process.
A full list of participating institutions can be found here.
As Becky Castellon, our Institutional Partnerships Manager, puts it: “Extending our agreement with Jisc is a reward for the strong partnership we’ve built with research institutions throughout the UK.”
At MDPI, we are dedicated to making research more accessible while reducing administrative burdens for institutions and authors. Open access publishing is at the heart of what we do, and we’re proud to expand its reach in the UK and beyond.
Inside MDPI
Visit to MDPI's Singapore office
During my January trip to some of our APAC offices, I also had the pleasure of visiting our Singapore office for the first time. It’s exciting to see how much the team has grown, now numbering over 55 staff members, with more joining us in February.
Welcoming and Supporting New Team Members
“Experienced staff play an important role in mentoring new hires”
I had the opportunity to connect with both experienced colleagues and new team members who are currently embarking on their careers. This visit reminded me of what it was like when I was in their shoes. I encourage all of us to engage new colleagues with empathy, as we have all been in their position. By creating a welcoming and supportive environment, we can help them settle in and learn about the corporate world, MDPI and our mission.
Experienced staff play an important role in mentoring and guiding new hires, most of whom are transitioning from academia to their first job. I’m especially grateful to colleagues such as Colin Chen, Alicia Ren, Yu Nwe Soe, Colin Wee, Amy Cham and other senior members who have contributed to shaping the culture and work environment in Singapore.
Building MDPI’s Positive Reputation
During my visit, I spoke with the office staff about the importance of their roles in building a positive reputation that helps create trust in MDPI. I shared how every interaction and communication point contributes to the marketing of MDPI and our journals. I also highlighted the career development opportunities available as MDPI continues to grow.
Connecting with the Singapore Marketing Team
I also spent time connecting directly with the Singapore Marketing team, which has quickly grown to 15 young and ambitious members. They are eager to learn and are actively contributing to our journal and corporate marketing activities. I shared insights into our corporate marketing structure and strategy and look forward to supporting them as they grow.
During the visit, I was joined by my colleague Dr. Constanze Schelhorn, Head of Indexing, who provided training on indexing. This training was greatly appreciated by the local staff.
Meeting with Prof. Dr. Manoj Gupta
Lastly, we had the privilege of meeting Prof. Dr. Manoj Gupta, Editor-in-Chief (EiC) of Technologies since 2016 and Section EiC of Metals.
Prof. Gupta is an active decision-maker for the journal and a great brand ambassador for MDPI.
Prof. Gupta has helped sustainably scale Technologies, which now has a 4.2 Impact Factor and a 6.7 CiteScore, ranking Q1 in the JCR category of Engineering and Q1 in the CiteScore category of Computer Science.
During our meeting, we discussed strategies for Institutional Open Access Partnership agreements and ways to promote MDPI journals in Singapore.
PS. During the visit, we also had the chance to participate in Lo Hei, also known as Yee Sang or the “prosperity toss.” This is a raw fish salad traditionally enjoyed during Chinese New Year and is particularly popular among Chinese communities in Singapore, Malaysia, and Indonesia. Everyone gathers around the table as the ingredients are added one by one, and then the salad is mixed together. It was a fun experience to take part in this New Year tradition!
Coming Together for Science
JAMS – Journal & Article Management System
I am excited to announce the official relaunch of JAMS (Journal & Article Management System), one of MDPI’s key initiatives to support academic publishers worldwide.
With this relaunch, JAMS now offers new pricing models and flexible solutions for small-scale journals, commercial publishers, and university presses. We have also redesigned the JAMS website to enhance the user experience.
“JAMS is a testament to our commitment to simplifying the publishing process”
Explore the new website here: jams.pub
It’s also great to see the JAMS team expanding our presence at conferences and on social media to engage more effectively with the academic community.
Recently, Facundo Santomé (Senior Marketing Manager) and Alex Ramos (Senior Marketing Specialist) represented JAMS at the APE 2025 conference in Berlin, highlighting how our platform empowers small and independent publishers to streamline and scale their journal management.
JAMS was built to change that by adapting to the unique requirements of each publisher.
At MDPI, we continually invest in our growth – not only by expanding our operations and staff but also by developing innovative products that serve the academic and publishing community at large. JAMS, with its comprehensive suite of journal management tools, is a testament to our commitment to simplifying the publishing process for our partners.
Imagine a submission system that frees up your time for strategy, innovation, and impactful publishing.
Under the leadership of Silvano Bonfatti (Product Manager, MDPI), the JAMS team has conducted in-depth market research to understand the challenges publishers face: endless administrative tasks, inefficient workflows, and systems that don’t always meet their needs.
If you believe JAMS could benefit any of your network contacts, please share our website. Contact the JAMS team. They are always ready to assist with your publishing needs.
What Sets JAMS Apart?
- Scalability – Whether you're a niche journal or managing thousands of submissions, JAMS grows with you.
- End-to-End Workflow – From submission to peer review and final publication, everything is in one place.
- Automation That Works for You – Say goodbye to chasing reviewers and formatting issues, so that you can focus on quality instead.
- Built by Publishers, for Publishers – JAMS is backed by MDPI’s expertise; we know exactly what it takes to run a journal smoothly.
- Flexible & Fair Pricing – Supporting journals of all sizes, with special rates for non-profits and publishers in the Global South.
Partners Who Already Trust JAMS
If you believe JAMS could benefit any of your network contacts, please share our website. Contact the JAMS team. They are always ready to assist with your publishing needs.
Closing Thoughts
Visit to MDPI's Bangkok office
To conclude my APAC trip, I had the pleasure of visiting our Bangkok office from 22 to 24 January. The office has grown significantly, closing 2024 with a total of 445 colleagues across various departments, including Editorial, Production, Conference, Training, Journal Relationship Specialists (JRS), Managing Editors, and supporting teams in HR, Admin, IT, and Finance.
I would like to praise our Bangkok management team for their excellent work in supporting our growth and creating a positive work environment. Our colleagues here are humble, talented, hardworking, and appreciative of MDPI’s mission.
Thailand was among MDPI’s top 30 markets in 2024 for total publications. With our office in Bangkok, we have an opportunity to further promote open access while supporting local researchers and institutions. This includes open access discounts, author training sessions, conference sponsorships, and other initiatives. We currently have 25 Editorial Board Members (EBMs) from Thailand and will work on expanding this network.
Engaging with Group Leads
“Group leads play an important role in creating a safe, positive environment”
During my visit, I met with our group leads to highlight their crucial role in managing journal performance and mentoring new employees, especially given our increased hiring targets. Many new hires are early in their careers and require training, development, and support. Group leads play an important role in creating a safe, positive environment that fosters professional growth while maintaining MDPI’s reputation for service quality.
To wrap up the session, I added a personal touch by holding the door and giving everyone high-fives – a small gesture to show appreciation, boost morale, and strengthen team spirit. It’s important for our colleagues to feel seen, heard, and valued.
University Visit: King Mongkut’s University of Technology North Bangkok (KMUTNB)
We also visited King Mongkut’s University of Technology North Bangkok (KMUTNB) to explore collaboration opportunities.
Our discussions focused on: Institutional Open Access Partnership (IOAP), Author training sessions, Conference sponsorships, Student employment initiatives, and more.
This visit reinforced the importance of building strong relationships with local universities, ensuring we continue to support and engage with the academic community in Thailand.
“My time in Bangkok was productive and inspiring”
My time in Bangkok was productive and inspiring. The senior team has done a great job in growing the office and creating a supportive, high-performing environment. I look forward to seeing continued success from our colleagues in Thailand.
Chief Executive Officer
MDPI AG
4 February 2025
World Cancer Day 2025—United in Every Journey
Cancer impacts millions of lives worldwide, yet each person’s journey with the disease is uniquely their own. World Cancer Day reminds us that while the disease impacts individuals differently, our shared strength, innovation, and focus on holistic care bring us closer to a future where cancer no longer dictates lives. Every experience, challenge, and success story contribute to the broader fight against cancer, demonstrating the resilience and hope that unite us all. As we continue to make strides through innovative research, treatment advancements, and global collaboration, it is essential to recognize both the diversity of stories and our common goal of overcoming cancer together.
In observance of this day, we invite you to explore the following resources that delve into the field of cancer and the cutting-edge advancements shaping its care. By prioritizing people-centered treatment where patients’ voices and needs guide care, we can ensure personalized attention for all. It is our hope to foster a deeper understanding of the impact of cancer and encourage meaningful action to support patients, caregivers, and researchers in their pursuit of a world free from cancer’s hold. Together, we can inspire action and work toward a cancer-free future.
 |
|
Biology & Life Sciences |
Medicine & Pharmacology |
Chemistry & Material Sciences Public Health & Healthcare Engineering Society |
 |
“Rare Variants of Dermatofibrosarcoma Protuberans: Clinical, Histologic, and Molecular Features and Diagnostic Pitfalls”
by Celestine M. Trinidad, Sintawat Wangsiricharoen, Victor G. Prieto and Phyu P. Aung
Dermatopathology 2023, 10(1), 54–62; https://doi.org/10.3390/dermatopathology10010008
“Nitrogen Containing Heterocycles as Anticancer Agents: A Medicinal Chemistry Perspective”
by Adarsh Kumar, Ankit Kumar Singh, Harshwardhan Singh, Veena Vijayan, Deepak Kumar, Jashwanth Naik, Suresh Thareja, Jagat Pal Yadav, Prateek Pathak, Maria Grishina et al.
Pharmaceuticals 2023, 16(2), 299; https://doi.org/10.3390/ph16020299
“Artificial Intelligence in Brain Tumor Imaging: A Step toward Personalized Medicine”
by Maurizio Cè, Giovanni Irmici, Chiara Foschini, Giulia Maria Danesini, Lydia Viviana Falsitta, Maria Lina Serio, Andrea Fontana, Carlo Martinenghi, Giancarlo Oliva and Michaela Cellina
Curr. Oncol. 2023, 30(3), 2673–2701; https://doi.org/10.3390/curroncol30030203
“Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook”
by Onyinyechi Obidiro, Gantumur Battogtokh and Emmanuel O. Akala
Pharmaceutics 2023, 15(7), 1796; https://doi.org/10.3390/pharmaceutics15071796
“Biomarkers in Breast Cancer: An Old Story with a New End”
by Lyvia Neves Rebello Alves, Débora Dummer Meira, Luiza Poppe Merigueti, Matheus Correia Casotti, Diego do Prado Ventorim, Jucimara Ferreira Figueiredo Almeida, Valdemir Pereira de Sousa, Marllon Cindra Sant’Ana, Rahna Gonçalves Coutinho da Cruz, Luana Santos Louro et al.
Genes 2023, 14(7), 1364; https://doi.org/10.3390/genes14071364
“Could Microbiome Be the Common Co-Denominator between Type 2 Diabetes and Pancreatic Cancer?”
by Marin Golčić and Andrej Belančić
Diabetology 2023, 4(4), 553–559; https://doi.org/10.3390/diabetology4040049
“Targeting Solute Carrier Transporters (SLCs) as a Therapeutic Target in Different Cancers”
by Ravi Bharadwaj, Swati Jaiswal, Erandi E. Velarde de la Cruz and Ritesh P. Thakare
Diseases 2024, 12(3), 63; https://doi.org/10.3390/diseases12030063
“Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer”
by Dimitrios Stefanoudakis, Maximos Frountzas, Dimitrios Schizas, Nikolaos V. Michalopoulos, Alexandra Drakaki and Konstantinos G. Toutouzas
Curr. Issues Mol. Biol. 2024, 46(4), 2827–2844; https://doi.org/10.3390/cimb46040177
“Metformin: From Diabetes to Cancer—Unveiling Molecular Mechanisms and Therapeutic Strategies”
by Emilia Amengual-Cladera, Pere Miquel Morla-Barcelo, Andrea Morán-Costoya, Jorge Sastre-Serra, Daniel Gabriel Pons, Adamo Valle, Pilar Roca and Mercedes Nadal-Serrano
Biology 2024, 13(5), 302; https://doi.org/10.3390/biology13050302
“Immune Checkpoint Inhibitors: Fundamental Mechanisms, Current Status and Future Directions”
by Abdullah Younis and John Gribben
Immuno 2024, 4(3), 186–210; https://doi.org/10.3390/immuno4030013
“Breast Cancer Screening among African Immigrants in the United States: An Integrative Review of Barriers, Facilitators, and Interventions”
by Julian I. Rauch, Joseph Daniels, Alyssa Robillard and Rodney P. Joseph
Int. J. Environ. Res. Public Health 2024, 21(8), 1004; https://doi.org/10.3390/ijerph21081004
“Predicting Leukoplakia and Oral Squamous Cell Carcinoma Using Interpretable Machine Learning: A Retrospective Analysis”
by Salem Shamsul Alam, Saif Ahmed, Taseef Hasan Farook and James Dudley
Oral 2024, 4(3), 386–404; https://doi.org/10.3390/oral4030032
 |
 |
 |
 |
 |
